Lee KH - Search Results

1

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH, Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG). Kim JY, et al. Among authors: lee ks, lee kh. Eur J Cancer. 2018 Nov;103:127-136. doi: 10.1016/j.ejca.2018.08.004. Epub 2018 Sep 14. Eur J Cancer. 2018. PMID: 30223226 Clinical Trial.

2

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Han SW, et al. Among authors: lee kh. Clin Cancer Res. 2006 Apr 15;12(8):2538-44. doi: 10.1158/1078-0432.CCR-05-2845. Clin Cancer Res. 2006. PMID: 16638863

3

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.

Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ. Lee KH, et al. Jpn J Clin Oncol. 2006 Jun;36(6):344-50. doi: 10.1093/jjco/hyl039. Jpn J Clin Oncol. 2006. PMID: 16818479

4

High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.

Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS. Lee KH, et al. Among authors: lee sh. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6. doi: 10.1158/1078-0432.CCR-05-2710. Clin Cancer Res. 2006. PMID: 16857796

5

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ. Han SW, et al. Among authors: lee sh, lee kh. Lung Cancer. 2006 Nov;54(2):201-7. doi: 10.1016/j.lungcan.2006.07.007. Epub 2006 Sep 7. Lung Cancer. 2006. PMID: 16956694

6

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.

Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Han SW, et al. Among authors: lee sh, lee kh. Pharmacogenet Genomics. 2007 May;17(5):313-9. doi: 10.1097/FPC.0b013e328011abc0. Pharmacogenet Genomics. 2007. PMID: 17429313

7

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Lee KH, et al. Among authors: lee sh. BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.

8

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH. Lee KH, et al. Among authors: lee sh. Lung Cancer. 2008 Jun;60(3):401-7. doi: 10.1016/j.lungcan.2007.10.014. Epub 2007 Nov 26. Lung Cancer. 2008. PMID: 18036700

9

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.

Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, Han SW, Song SH, Oh DY, Kim TY, Bang YJ. Lee KH, et al. Among authors: lee j. Cancer Lett. 2010 Dec 18;299(1):22-8. doi: 10.1016/j.canlet.2010.07.020. Epub 2010 Aug 19. Cancer Lett. 2010. PMID: 20727673

10

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.

Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Lim KH, et al. Among authors: lee kh. Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26. doi: 10.1007/s00280-011-1584-1. Epub 2011 Feb 17. Cancer Chemother Pharmacol. 2011. PMID: 21327930 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,024 results

Search Page

Filters